Given its pivotal role in cancer metabolism, G6PD is considered a promising target for cancer therapy. Inhibiting G6PD could disrupt the redox balance in cancer cells, leading to increased oxidative stress and reduced biosynthetic capacity. Several studies have explored the use of specific G6PD inhibitors to selectively target cancer cells without affecting normal cells, which typically have lower G6PD activity. However, challenges remain in developing effective and selective inhibitors that can be used in clinical settings.
